Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Helius Medical Technologies ( (HSDT) ).
Helius Medical Technologies, Inc. faced a compliance issue with Nasdaq’s minimum stockholders’ equity requirement after their equity fell below $2.5 million as of December 31, 2024. On June 6, 2025, the company completed a public offering raising approximately $8.1 million, which helped them meet the equity requirement. As of June 17, 2025, Helius Medical Technologies believes it has regained compliance and awaits Nasdaq’s confirmation for continued listing.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies scores low due to significant financial challenges, characterized by ongoing losses and negative cash flow. Technical analysis confirms bearish momentum, with the stock being oversold. The valuation is unattractive with a negative P/E ratio and no dividend yield. Without positive earnings call or corporate events data to offset these negatives, the stock faces a challenging outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Average Trading Volume: 5,711,429
Technical Sentiment Signal: Strong Sell
Current Market Cap: $174.3K
For a thorough assessment of HSDT stock, go to TipRanks’ Stock Analysis page.